Evolus (EOLS) Total Non-Current Liabilities (2017 - 2022)
Evolus (EOLS) posted Total Non-Current Liabilities of $159.5 million for Q4 2022, down 2.46% on a QoQ basis from $163.5 million in Q3 2022, and up 21.87% year-over-year from $130.9 million in Q4 2021.
Evolus (EOLS) Total Non-Current Liabilities (2017 - 2022) Analysis & Trends
Evolus' Total Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $159.5 million for Q4 2022.
- Quarterly Total Non-Current Liabilities rose 21.87% year-over-year to $159.5 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $159.5 million (up 21.87% YoY) and the FY2022 annual result came in at $159.5 million, up 21.87% from the prior year.
- Total Non-Current Liabilities was $159.5 million for Q4 2022 at Evolus, down from $163.5 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $240.5 million in Q4 2020 and bottomed at $34.8 million in Q1 2018.
- A 5-year average of $116.2 million and a median of $117.3 million in 2020 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2018 — Total Non-Current Liabilities sank 83.64% — and 2019, when it jumped 225.1%.
- Evolus' Total Non-Current Liabilities stood at $37.3 million in 2018, then jumped by 212.14% to $116.3 million in 2019, then surged by 106.77% to $240.5 million in 2020, then tumbled by 45.58% to $130.9 million in 2021, then climbed by 21.87% to $159.5 million in 2022.
- Business Quant data shows EOLS's Total Non-Current Liabilities at $159.5 million in Q4 2022, $163.5 million in Q3 2022, and $164.1 million in Q2 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 14.92 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 18.28 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 33.47 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 20.09 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.24 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.26 Bn |
| 10 | Evolus | 390.47 Mn | 340.68 Mn | 48.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 159.48 Mn |
| Sep 30, 2022 | 163.50 Mn |
| Jun 30, 2022 | 164.06 Mn |
| Mar 31, 2022 | 153.41 Mn |
| Dec 31, 2021 | 130.87 Mn |
| Sep 30, 2021 | 112.82 Mn |
| Jun 30, 2021 | 128.73 Mn |
| Mar 31, 2021 | 128.91 Mn |
| Dec 31, 2020 | 240.48 Mn |
| Mar 31, 2020 | 117.33 Mn |
| Dec 31, 2019 | 116.30 Mn |
| Jun 30, 2019 | 114.43 Mn |
| Mar 31, 2019 | 99.67 Mn |
| Dec 31, 2018 | 37.26 Mn |
| Sep 30, 2018 | 37.31 Mn |
| Jun 30, 2018 | 35.20 Mn |
| Mar 31, 2018 | 34.81 Mn |
| Dec 31, 2017 | 227.78 Mn |